Myomo, Inc. ( MYO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Paul Gudonis - President, CEO & Chairman David Henry - Chief Financial Officer Conference Call Participants Tirth Patel Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Scott Henry - Alliance Global Partners, Research Division Anthony Vendetti - Maxim Group LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good day, and welcome to the Myomo Third Quarter 2025 Financial Results Conference Call.
Myomo, Inc. (MYO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.
Myomo, Inc. (MYO) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Paul R. Gudonis CEO | AMEX Exchange | US62857J2015 ISIN |
| United States Country | 101 Employees | - Last Dividend | 31 Jan 2020 Last Split | - IPO Date |
Myomo, Inc. operates within the forefront of wearable medical robotics, centered on conceiving, developing, and manufacturing myoelectric orthotics specifically designed for individuals afflicted by neuromuscular disorders. The company's operational footprint extends across the United States, China, Germany, and various international markets. Since its establishment in 2004, Myomo has been dedicated to improving the quality of life for people dealing with the consequences of neuromuscular conditions. With its headquarters nestled in Boston, Massachusetts, Myomo, Inc. has been a beacon of innovation, empowering adults and adolescents facing challenges from brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, among other neurological disorders, to regain function and independence in their daily activities.
Marketed as a myoelectric-controlled upper limb brace, or orthosis, MyoPro stands out as Myomo's flagship product designed to assist patients whose arms have become weak or paralyzed. This innovative device enables users to carry out functional daily living activities by providing the necessary support to the affected limb. By harnessing myoelectric signals from the user's muscle movements, MyoPro facilitates greater arm mobility and function, embodying a leap forward in assistive technology.
Building upon the foundational technology of its predecessor, MyoPro 2 integrates advanced control technology, configuration software, and user interface enhancements. A significant feature of MyoPro 2 is the inclusion of a pop-out battery, which extends the device's usage time, thereby promoting longer periods of independence and activity without necessitating frequent recharging.
Representing the pinnacle of Myomo's technological advancements, MyoPro2+ encompasses a series of improvements over the MyoPro 2. This iteration introduces 3D printed orthotics capabilities, further software enhancements, and a redesigned interface for easier donning and doffing of the device. The MyoPro2+ caters directly to the user's need for a more personalized and comfortable fit, coupled with increased efficiency and user-friendliness, making it a premier solution for those seeking to overcome upper limb paralysis or weakness.
Myomo’s distribution strategy traverses a wide spectrum of sales channels, including partnerships with orthotics and prosthetics providers, collaborations with the Veterans Administration, and an extensive network of distributors. This multifaceted approach ensures that Myomo's groundbreaking products are accessible to a broad audience, including those who might benefit the most from wearable medical robotics technologies.